195 related articles for article (PubMed ID: 9314012)
1. Sulfonylureas.
Zimmerman BR
Endocrinol Metab Clin North Am; 1997 Sep; 26(3):511-22. PubMed ID: 9314012
[TBL] [Abstract][Full Text] [Related]
2. Oral hypoglycemic agents in type II diabetes mellitus.
Lubbos H; Miller JL; Rose LI
Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
[TBL] [Abstract][Full Text] [Related]
3. Glimepiride for NIDDM.
Med Lett Drugs Ther; 1996 May; 38(975):47-8. PubMed ID: 8632731
[No Abstract] [Full Text] [Related]
4. Sulphonylureas in the treatment of non-insulin-dependent diabetes.
Ferner RE; Alberti KG
Q J Med; 1989 Nov; 73(271):987-95. PubMed ID: 2695959
[No Abstract] [Full Text] [Related]
5. [Hypoglycemic sulfamides: new pharmacologic data and practical implications].
Blickle JF; Brogard JM
Diabetes Metab; 1998 Jun; 24(3):276-80. PubMed ID: 9690064
[No Abstract] [Full Text] [Related]
6. The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
Del Prato S; Pulizzi N
Metabolism; 2006 May; 55(5 Suppl 1):S20-7. PubMed ID: 16631807
[TBL] [Abstract][Full Text] [Related]
7. Exploring the role of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus.
Graham JP; Stam D
Pharm Pract Manag Q; 1997 Oct; 17(3):1-9. PubMed ID: 10173306
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and Characteristics of Sulfonylureas and Glinides.
Lv W; Wang X; Xu Q; Lu W
Curr Top Med Chem; 2020; 20(1):37-56. PubMed ID: 31884929
[TBL] [Abstract][Full Text] [Related]
9. Are sulfonylureas passé?
Green JB; Feinglos MN
Curr Diab Rep; 2006 Nov; 6(5):373-7. PubMed ID: 17076998
[TBL] [Abstract][Full Text] [Related]
10. Sulfonylureas in NIDDM.
Groop LC
Diabetes Care; 1992 Jun; 15(6):737-54. PubMed ID: 1600834
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
12. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
13. Pioglitazone/glimepiride (Duetact) for diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
[No Abstract] [Full Text] [Related]
14. The second-generation sulfonylureas: change or progress?
Kreisberg RA
Ann Intern Med; 1985 Jan; 102(1):125-6. PubMed ID: 3966729
[No Abstract] [Full Text] [Related]
15. [Risk and benefit of sulfonylureas--their role in view of new treatment options for type 2 diabetes].
Rustenbeck I
Med Monatsschr Pharm; 2016 Feb; 39(2):65-72; quiz 73-4. PubMed ID: 26983335
[TBL] [Abstract][Full Text] [Related]
16. Beyond sulfonylureas: new oral medications in the treatment of NIDDM (type II DM).
Capriotti T
Medsurg Nurs; 1997 Jun; 6(3):166-9. PubMed ID: 9238992
[No Abstract] [Full Text] [Related]
17. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
Rosenkranz B
Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
[TBL] [Abstract][Full Text] [Related]
18. [40 years of using sulfonylurea derivatives for treatment of diabetes].
Sieradzki J
Przegl Lek; 1996; 53(9):641-6. PubMed ID: 8992529
[TBL] [Abstract][Full Text] [Related]
19. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 1998 Oct; 32(10):1044-52. PubMed ID: 9793597
[TBL] [Abstract][Full Text] [Related]
20. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons".
Heine RJ
Horm Metab Res; 1996 Sep; 28(9):522-6. PubMed ID: 8911991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
